NEW YORK, Jan. 29, 2014 (GLOBE NEWSWIRE) -- The Rosen Law Firm, P.A. today announced that a class action lawsuit has been filed on behalf of purchasers of the securities of Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR) between March 15, 2012 and January 9, 2014, inclusive (the "Class Period") seeking remedies under the federal securities laws.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY CHOOSE TO DO NOTHING AT THIS POINT AND REMAIN AN ABSENT CLASS MEMBER.
According to the suit defendants issued materially false and misleading statements about Aegerion's true business condition because the Company allegedly marketed its drugs in violation of the FDCA. On January 10, 2014, Aegerion announced that it received a subpoena from the U.S. Department of Justice requesting documents regarding the Company's marketing of Juxtapid. The lawsuit claims this adverse information caused the price of Aegerion's stock price to fall, damaging investors.
If you wish to serve as lead plaintiff, you must move the Court no later than March 17, 2014. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the case, or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. of The Rosen Law Firm, toll-free, at 866-767-3653, or via e-mail at pkim@rosenlegal.com. You may also visit the firm's website at http://rosenlegal.com.
The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.